Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01559103 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01559103 is a Phase 1 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 39 participants.
The verdict
NCT01559103, a Phase 1 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients
Interventions
- BIOLOGICAL MEDI5117
- BIOLOGICAL MEDI5117 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-05-31 |
| Est. Completion | 2014-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01559103
The ClinicalTrials.gov registry entry for NCT01559103 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI5117 is the first listed.
NCT01559103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01559103 about?
NCT01559103 is a clinical study titled "Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients". Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients
What is the current status of trial NCT01559103?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2012-05-31. Estimated completion is 2014-02-28.
What interventions are being tested in trial NCT01559103?
The interventions under investigation include: MEDI5117 (BIOLOGICAL), MEDI5117 Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT01559103?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.